0.5mg/ml 0.5mg/ml gege tata inin A) A) 150mg/hr150mg/hr B) B) 300mg/hr300mg/hr C) C) 2.5mg/hr2.5mg/hr D) D) 5mg/hr5mg/hr ti ti ouou thth 100mg/QID 100mg/QID 5050mgmg/$/$ 0.0.3030 40mg/BID 40mg/BID 20mg/$20mg/$ 00450045 12 12mgmg/$/$ 0.0.9191 B o B o C &C & -W -W e a e a Eq.wt Eq.wt it it inin g#g# oMRoMR q5q5 lala irir nsns -T -T gSgS gS gS Pr
Rx Rx On
Ondadansnsetetroro HCHC ch
chererryry sysyruru 6 t 6 t ) 9) 9 2 t2 t 0 t0 t ma ma 5 d 5 d 5 d5 d s s s s )3 )3 re
renana clcleaeararancnce,e, ifif atat enen 2 L 2 L 6 L6 L 9 L9 L e o e o 1 L 1 L ) 2) 2 c) c) .4.4 d)d)1.1.2323 daday- y-b)0 b)0.5.5 mimin-n- -1-1 d)d)3.3. mimin- n-MgC0 MgC0 Pr
0 m 0 m (Mg (Mg 84.384.3 A-4.3g A-4.3g has has ri ri hu
humama ininteteststininalal flflorora?a? b ) b ) e)
e) PsPseueudodomomonana aeaerurugiginonosasa
)C )C he
hemomolylytiti didiseseasas
b) b) ) L ) L es es rmrm ) V ) V re re c) c) d)6d)6 fo fo rere il
ilatatatatioio atat thth ininititiaia haha acacutut ininflflamammama ioio I-I- I- I-I o I o ) I) I I oI o I aI a I oI o , I, I , a, a Pr Pr tetectct coco riri htht anan rere enen iriracac
E-E-T4T4 cecellll )G )G c) c) ChCh lele erer d)
d) CaCarbrbohohydydraratete
Pr
part part an
anotothehe tytypepe
il il b)
b) DeDe rereasas popotatassssiuiu pepermrmeaeabibililityty c)
c) InIn rere sese popotatassssiuiu pepermrmeaeabibililityty
ti
ti tete
B.
B. prpropopylylththioioraracici
E.
E. prprololonongege exexpoposusu toto olol enenviviroronmnm ntnt
st st
ro
b)
b) c)c) e)e)
synthetase synthetase
a)
a) 1,21,25-d5-dyhyyhyroxroxychycholeolecalcalcifciferoero b)
b) 25-25-hydhydroxroxychycholeolecalcalcifciferoero c)
c) 7-d7-dehehydydrorochchololesesteteroro d)
d) ChChololesescacalclcififererolol
reaction reaction ac
tissue? tissue?
c)
c) NoNorerepipinenephphririnene
a)
a) DeDetotoxixifificacatitionon b)
b) GlGlucucononeoeogegenenesisi ig ig th th di diclcl fefenana B.
B. PrPropopoxoxypyphehenene C.
C. IbuprofenIbuprofen D.
D. InIndodomemeththacacinin E. E. NaproxenNaproxen te te ltlt isis ny ny xexedede oror hy
hypopogogonanadidismsm ip ip ti ti le le tutu le le lala itit 53
53-Wh-Whicic ofof thth olollolo inin bebestst dedescscriribebe thth coco didititionon knknowow hyhypopoprprotothrhromom ininememinin ta
to
to chchararacacteteririzeze thth heheadadacachehe A.
A. TuTumomoririgegenini B.
B. VaVascsculularar-m-migigrarainin C.
C. MuMuscsc onontrtracac ioio
A.
A. hyhypepertrthyhyroroididisis C.
C. hyhypopoththyryroioididismsm ad
adrerenana ypypererplplasasiaia
-Wh -Wh
I o
I o ) I) I I oI o
wo
woulul inincrcreaea thth ririsksk hehemomorrrr agage?e? A. A. -Wh -Wh hyperkalemia? hyperkalemia? II
III.I. sosodidiumum popolylyststyryrenen susulflfononatat I o
I o ) I) I d Id II oI o I oI o , a, a
-Th -Th
Pr
-W -W infection? infection?
A.
A. efefototetetanan (c(cefefototanan B.
B. efeftrtr axax nene (R(R cecephphinin C.
C. ErErytythrhromomycycinin
-W -W su
suffffererinin frfromom didiababeteteses memellllititusus
C.
C. urur arar etetenentitionon ly
lycoco urur
62
62-P-Patat enentsts ususinin mimi dadaririnene (C(C rdrdararonone)e) shshououldld momoninitotorere fofo
) I
) I ) I) I I oI o I aI a I oI o I aI a I oI o e)e) not
not ncnc ududeded thth ecechnhnicic anan rere popo sisibibililititieses am
ambubulalatotoryry cacarere prpracactiticece B.
B. ReRe omommeme didingng ththererapapeueu icic alal erernanatitiveve hehe rerescsc ibibinin phphysysicic anan In
In enen oror mamainin enenanancece 64
64-A-A haharmrmacac stst eeee toto dede titifyfy anan erer-t-t e-e-coco ntnterer ugugarar-f-freree,e, alalcoco olol-f-frere cocougug foformrm lala co
co tata niningng guguaiaifefenene inin anan dede trtromometethohorprpanan owow cocoulul hihi ueueststioio bebe clclasas ifif eded A.
A. AvAvaiailalabibililityty B.
B. StStororagageses/s/statabibililityty D.
D. CaCalclcululatatioio
A.
A. PhPhararmamaceceututicicalal alalteternrnatativiveses B.
B. PhPhararmamacece titicaca eqequiuivavalele tsts C.
C. ThThererapapeueutiti alalteternrnatativiveses D.
D. ThThererapapeueutiti eqequiuivavalelentnt Bi
Bi lologigicaca eqequiuivava enen
Pr
a. a. FillersFillers c. c. LubricantsLubricants d. d. DispersantDispersant gr
grananululatatioio isis
-W -W -W -W -Wh -Wh 2-W
2-W icic hehe fofo lolowiwingng roroututeses ofof adadmimininiststrara ioio prpr vividede fofo hehe rereatateses ioioavavaiailalabibililityty
st
74
74-A-A lalargrg vovolulu IVIV vo volulu eses oror orore?e? a. a. 1010mlml it it tete tete toto trtr -W -W lo lo isis sususpsp of
of itit seseveverere totoxixi itity?y?
-Wh -Wh titi ll ll sysy thth lolo it it Copyright Copyright
B. B.
E. E.
di
dissssololututioio raratete
Fl
Fl ccccululatateded sususpspenen ioionsns
f t f t
f t f t
f t f t
a.
a. elelaxaxatatioio brbronon hihialal smsmoooo mumu clcl anan roroncnc odod lalatiti
-Wh -Wh
A-A-SuSu tata rere eaea sasagege frfr
B-B-CoContntrorolllleded rereleleasaseded dodosasagege foformrm So
Solulu onon agag foformrm
D-D-SlSlowow rere eaeasese sasa foformrm E-M
E-Micicroroememululsisionon dodosasagege foformrm ch
ch thth fofo owow rere onon eses isis memedidiatateded rara mpmpatat eteticic mumu cacariri rerececeptpt rsrs
ac ac atatioio e)
HC
HC anan epep inin gege
e)
e) MuMucucu anan epep ininogogenen
include include I.I. II. II. III. III. days days , I , I E-fatigue E-fatigue be
be yoyourur rerecocommmmenendadatitionon
b)
b) acacetetamamininopophehe
- 2 - 2
To
Totaltal liliabiabililitietie $75,000$75,000
ur
urrere liliabab lili ieie
02
02 nsns rara coco papaninieses ayay oror thth ruru heapheapeses riricece tititutu eded meme icicatat s.s.
of$0.60/tablet of$0.60/tablet $1.90/tablet $1.90/tablet . 3 . 3O/tabletO/tablet of$0.50/tablet of$0.50/tablet 3.
3. olol inin arar imimpoportrtanan unun amamenentata ririncncipip eses mama keketiti PTPT
ri
ri ryry cocontnt enencece isis NONO agaggrgravavatateded byby
I o
I o ) I) I I oI o I oI o
lu
lu ioio onon aiai ntntamam cicin,n, etet ylyl ararabab n,n, soso iuiu enenzozoatate,e, anan didi didi ed
edenentatatete CoCorrrr ctct atatemem ntnt(s(s bobo atat lulu ioio mama clcludud
I o
I o ) I) I I oI o I oI o , a, a
- 2 - 2
I o
I o ) I) I I aI a I oI o I oI o , a, a
dr
dr iningege tete ororalallyly
Ca
Carbrb dodopapa isis avavaiai abab e,e, fofo ararenen ereralal adadmimi isistrtratatioio
A.
A. CaCarbrb dodopapa crcr sssseses thth lolo rarainin babarrrr erer
Ca
Carbrbididopop avavaiailala lele fofo ararenen ereralal adadmiminini trtratatioio
E. E. -W -W glaucoma. glaucoma. 11
112-2- 3-3- eaear-r-olol mamalele rerecece vivingng ylylenen ap
apprpr prpriaia chch icic fofo coco ststipipatat onon asassosociciatateded itit cocodede nene
Pr
-W -W re
reduducece teteroroidid osos
ma ma I o I o I oI o )1)1 114-114- E.E. ColiColi 11
116-W6-W icic hehe fofollllowowinin tata ememenen abab utut rara hyhypopoglgl cecemimicscs arare/e/isis cocorrrrecec
A-A-ChChlolorprproropapamimidede blblococksks ininsusulili rerececeptptoror
B-B-GlGlipipizizidid inincrcreaeasese glglucucagagonon sesecrcretetioionsns -T
-T
1l
1l7-7-MeMe abab lili prpr duductct ofof iaiacici ncnc udude:e: I o
I o I oI o III-NicotineIII-NicotineI oI o )1)1 18
18-I-I igig xixin,n, inincrcreaeasese inin hyhydrdroxoxylyl grgr upup haha ncncrereasaseses ololararitity!y! -I
-Incncrereasas duduraratitionon acactitionon B-D
B-Dececrereasas duduraratitionon ofof acactitionon C-N
C-N
mi mi
1-1-L-HisL-Histadtadineine decdecarbarboxyoxylaslas
II-L-II-L-hishistadtadineine carcarboxboxylaylasese III-L-h
III-L-hististidiidinene hydhydroxroxylaylasese I o
I o ) I) I I oI o I aI a I oI o I oI o )1)1 -T
-T
A-A-SeSelelectctiviv COCO nhnhibibitit
B-B-SeSe ecectitiveve COCO IIII nhnhibibitit
D-D-AceAcetyty latlat cyccycloolooxygxygenaenasese
E-E-InInhihibibitsts lilipopoxyxygegenanasese asaswewellll asas cycyclclooooxyxygegenanasese 12l-Serotonin:
12l-Serotonin: A-Imidazole
A-Imidazole B-tryptophanB-tryptophan
Pr
E-pyrrolidine E-pyrrolidine
) I
) I IIII I aI a I oI o IIII IIII
12
123-3-FiFilglgraraststinin isis
mu mu momo Erythropoietins Erythropoietins D-OprelvekinE-mo mo
I-I- ememogoglolobibi (o(oxyxygege cacarrrr erer blblooood)d)-p-poror hyhyriri tete rarameme II
II-M-Myoyoglglobobinin (o(oxyxygege cacarrrrieie inin titissssueue)-)-momononomemer.r.
II
II -C-Cytytocochrhromom oxoxididasase.e.
) I
) I IIII I aI a I oI o IIII , I, I IIII
A-A-PoPosisititiveve scschihizozophphrerenini sysympmptotomsms
B-B-NeNegagatitiveve scschihizozophphrerenini sysympmptotomsms
C-C-PoPosisititiveve anan nene atat veve sysympmptotomsms D-De
D-Deprpresessisionon anan scschihizozophphrerenini
E-E-SeSeizizurureses anan dedeprpresessisionon
jec jec Comprehensiveness Comprehensiveness -T -T -T -T Copyright Copyright - 2- 2
profit profit
l-l-BaBalalancnc shsheeee
II-II-ReRetatainin eaearnrninin ststatatememenen II
III-I-InIncocomeme ststatatememenen I o
I o I oI o 1,1,
33
33-W-W atatisis SFSF-3-3 36
36 E-E-PaPatitienen nono clclininicicalal ininfoformrmatatioio
C-C-GeGenenerara hehealalthth ststatatusus D-D-ShShoror fufuncnctitionon
mp
mp rtrtanan memetata ololisis reacreac ioion.n. ThTh trtranansfsferer tete raracycyclcl nene epep -t-tetetraracycyclcl nene caca lele
13
135-5-SiSimemeththiciconon isis pr
prototecectitiveve agagenen
D-D-BlBloooo didilalatitionon cacaususeses ananeueuryrysmsm 139.
139. ErytErythromyhromycin:cin:
I-I- isis rorotete sysyntnthehe isis nhnhibibititoror
19 19
II
II isis efeffefectctiviv agagaiainsns grgramam-p-p sisititiveve cococccci.i. ) I
) I I aI a I oI o onlyonly e)e)1,1, IIII anan
14
141-1- icic OTOT ncnc ududeded ststatat ststicic
-A -Anana ysysisis ofof -Yo -Yo -N -Namam upup lilierer mg/ml? mg/ml? Copyright Copyright - 2- 2 2020
fo
foodod cocontntaiaininingng hihighgh cacarbrbohohydydraratetes.s.
-Le -Le
E-R
E-Refeferer erer ememerer enencycy
co
confnfididenentitialalitity)y) -Y
-Y
Se
